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Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events
Kevin Y. Xu, MD, MPH; Ned Presnall, MSW; Carrie M. Mintz, MD; Jacob T. Borodovsky, PhD; Nisha R. Bhat, BA; Laura J. Bierut, MD; Richard A. Grucza, PhD

Abstract
IMPORTANCE Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD)
are understudied and undertreated. It is unknown whether the use of medications to treat OUD is
associated with reduced risk of alcohol-related morbidity.
OBJECTIVE To determine whether the use of OUD medications is associated with decreased risk for

Key Points
Question Are opioid use disorder
(OUD) medications associated with
alcohol-related poisonings, falls, and
injuries in persons with OUD and
co-occurring alcohol use?

alcohol-related falls, injuries, and poisonings in persons with OUD with and without co-

Findings This case-control cohort study

occurring AUD.

of 13 335 individuals with OUD from a
large, nationally representative data set

DESIGN, SETTING, AND PARTICIPANTS This recurrent-event, case-control, cohort study used

found that patients prescribed OUD

prescription claims from IBM MarketScan insurance databases from January 1, 2006, to December

medication had significant reductions in

31, 2016. The sample included persons aged 12 to 64 years in the US with an OUD diagnosis and

alcohol-related acute events.

taking OUD medication who had at least 1 alcohol-related admission. The unit of observation was
person-day. Data analysis was performed from June 26 through September 28, 2020.

Meaning The use of OUD medication in
opioid-dependent patients with
co-occurring alcohol use may hold

EXPOSURES Days of active OUD medication prescriptions, with either agonist (ie, buprenorphine
or methadone) or antagonist (ie, oral or extended-release naltrexone) treatments compared with
days without OUD prescriptions.
MAIN OUTCOMES AND MEASURES The primary outcome was admission for any acute alcoholrelated event defined by International Classification of Diseases, Ninth Revision and International
Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes. Conditional
logistic regression was used to compare OUD medication use between days with and without an

promise in reducing alcohol-related
acute events, but more investigation
is needed.
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alcohol-related event. Stratified analyses were conducted between patients with OUD with and
without a recent AUD diagnostic code.
RESULTS There were 8 424 214 person-days of observation time among 13 335 participants who
received OUD medications and experienced an alcohol-related admission (mean [SD] age, 33.1 [13.1]
years; 5884 female participants [44.1%]). Agonist treatments (buprenorphine and methadone) were
associated with reductions in the odds of any alcohol-related acute event compared with
nontreatment days, with a 43% reduction for buprenorphine (odds ratio [OR], 0.57; 95% CI, 0.520.61) and a 66% reduction for methadone (OR, 0.34; 95% CI, 0.26-0.45). The antagonist treatment
naltrexone was associated with reductions in alcohol-related acute events compared with
nonmedication days, with a 37% reduction for extended-release naltrexone (OR, 0.63; 95% CI, 0.520.76) and a 16% reduction for oral naltrexone (OR, 0.84; 95% CI, 0.76-0.93). Naltrexone use was
more prevalent among patients with OUD with recent AUD claims than their peers without
AUD claims.
CONCLUSIONS AND RELEVANCE These findings suggest that OUD medication is associated with
fewer admissions for alcohol-related acute events in patients with OUD with co-occurring AUD.
JAMA Network Open. 2021;4(2):e210061. doi:10.1001/jamanetworkopen.2021.0061
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Introduction
Over the last decade, an unprecedented epidemic of drug-related poisonings has affected countries
spanning North America and Europe. Recent estimates of unintentional poisoning deaths (19.1 deaths
per 100 000) have eclipsed those of falls (11.4 deaths per 100 000) and motor vehicle traffic deaths
(11.6 deaths per 100 000).1 This is evidenced by an all-time high of 70 980 overdose deaths in the US
in 2019.2 Although the medical community has largely focused on the central role of opioid use
disorder (OUD), polysubstance use has been underrecognized, even though most patients with
substance use disorder use multiple substances,3 and the presence of multiple substance use
disorders is associated with worse treatment outcomes.4-6
Alcohol is the most commonly misused substance, both as a standalone drug and in the context
of polysubstance use.5 More than 25% of patients with OUD exhibit problematic alcohol use, and,
therefore, mitigation of risk for incident or recurrent alcohol use disorder (AUD) presents a salient
problem in the treatment of OUD.5,7-9 As central nervous system depressants,10 alcohol and opioids
can be lethal in combination, leading to increased overdoses and mortality among patients with
OUD,11,12 in addition to increased health care utilization.13-15 Because problematic alcohol and opioid
use are traditionally studied as independent conditions, limited evidence-based strategies exist for
mitigation of alcohol-related risk among patients with OUD.
Despite the therapeutic challenge of treating alcohol and opioid co-use, there is reason to
believe that existing OUD medications may hold promise in treating comorbid AUD, thus potentially
reducing alcohol-related risk among patients with AUD. For instance, some treatment options for
dual-diagnosis patients overlap, such as naltrexone, which holds dual US Food and Drug
Administration (FDA) indications for OUD and AUD treatment and has been found to be used more
commonly in patients with both OUD and AUD than patients with OUD but without comorbid AUD
(Mintz CM, Presnall NJ, Xu KY, et al, unpublished data, November 2020). However, few studies have
directly evaluated the efficacy of OUD medications on alcohol-related outcomes among patients
with OUD,15 and the limited research base has been marked by inconsistent results. For instance,
although an open randomized study16 suggested that methadone and buprenorphine suppressed
alcohol intake in heroin users, other analyses17 have not replicated these effects, with some studies18
showing increased problematic use of alcohol after initiation of opioid agonist treatment. Existing
studies16,17,19 are also characterized by short follow-up periods, modest sample sizes, and selfreported data.
Given the research gaps on alcohol-related outcomes among patients with OUD, our study used
the IBM MarketScan Commercial and Multi-State Medicaid databases (2006-2016) to evaluate the
association of 3 OUD medication treatments—buprenorphine, methadone, and naltrexone—with
emergency and inpatient admissions for acute alcohol-related events, specifically falls, injuries, and
poisonings in patients with OUD.

Methods
Study Overview
This case-control cohort study used a repeated-event, case-control design using the MarketScan
pharmaceutical claims data. We studied whether alcohol-related acute medical events were
associated with OUD pharmacologic treatment. This design used each subject as his or her own
control by comparing OUD medication use (exposure) at the time of event with exposure during
control periods. Thus, the exposure variable was various types of OUD pharmacologic treatments,
and the outcome variable was alcohol-related acute events. We also examined whether patients with
known recent AUD claims were more likely to receive naltrexone, given its dual FDA indications for
AUD and OUD, as opposed to buprenorphine and methadone, and whether the association between
OUD medication and alcohol-related events varies by the presence of recent AUD claims.
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Study Setting
The MarketScan databases represent claims from both employer-sponsored and Medicaid insurance
holders in the US.20 This captures longitudinal information on inpatient and outpatient health care
utilization, diagnosis codes based on the International Classification of Diseases, Ninth Revision
(ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision (ICD-10), and procedure codes. Prescription medication data provided information on
medication quantity, dosing, and fill dates. Commercial data were available from January 1, 2006, to
December 31, 2016. Medicaid data were available from January 1, 2011, to December 31, 2016.
Because all data were deidentified, our study was exempt from human subjects review and the need
for informed consent by the institutional review board at Washington University. This study follows
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and RECORD-PE
reporting guidelines.

Participants
Our analytic sample was derived from a previously described cohort of 304 676 individuals in the US,
aged 12 to 64 years, who had prescription drug coverage, a diagnosis of OUD, at least 1 OUD claim
during enrollment, and continuous insurance enrollment.20 Figure 1 depicts the derivation of our
final analytical sample. Because we used a case-control design, we limited analyses to the 29 157
individuals with alcohol-related acute events (ie, 275 519 individuals were ineligible because they did
not experience the outcome of interest). The first event for each person subsequent to initiating
OUD treatment was defined as the index event. The index event date was used to generate a
longitudinal data set at the day level containing all days in which a given individual was observed (ie,
covered by insurance), up to 1 year before and after the index event; that is, the final data set
contained 1 record per day per person, with the units of observation being person-days. Our decision
to choose a 2-year maximum observation window was guided by the mean length of time individuals
were observed in our data set, which was approximately 2 years. The selection of a standard, 2-year
observation window also helps fulfill the case-control design’s requirement of a stable within-person
probability of exposure over a defined period.21
Finally, we further limited our analyses to individuals who received OUD medication at least
once, thus excluding 15 822 individuals who never received any pharmacotherapy for OUD
(buprenorphine, naltrexone, and methadone). Participants were permitted to contribute multiple
events as long as they fell within a maximum of 1 year before and after the index event.

Figure 1. Flowchart for Development of Analytical Sample
304 676 Individuals aged 12 y and older with a diagnosis of OUD in
the MarketScan databases who had prescription drug coverage
and at least 1 OUD claim falling during period of enrollment

275 519 Individuals without alcohol-related
acute events excluded

29 157 Individuals included

15 822 Individuals who never received OUD medication
(naltrexone, methadone, buprenorphine) excluded

13 355 Individuals with 8 424 214 person-days in the 1 year before
and after index alcohol-related acute event included
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enrollment. The analytical sample was subsequently
restricted to observations within 1 year before and 1
year after index alcohol-related acute event to
decrease heterogeneity in observation time,
contributing a total of 8 424 214 person-days in the
study database.

February 24, 2021

3/11

JAMA Network Open | Substance Use and Addiction

Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events

Variables
Our primary outcome was emergency department visit or inpatient hospitalization for any alcoholrelated acute event during insurance enrollment. Such events were defined on the basis of
established methods and ICD-9 and ICD-10 codes22 as either (1) 100% alcohol-attributable acute
events (eg, alcohol poisoning) or (2) health care encounters involving an alcohol-related diagnosis
(eg, alcoholic liver disease or chronic alcohol dependence) in combination with acute events that are
known to be associated with excess alcohol use (eg, falls, injuries, and poisonings).22
Our primary exposure variable was OUD medication by days, operationalized as days
characterized by the presence or absence of prescription coverage or procedure codes for
buprenorphine, methadone, or naltrexone (oral or extended-release). Specific national drug codes
(buprenorphine and oral naltrexone) and procedure codes (methadone and extended-release
naltrexone) can be found elsewhere.20 We assumed that the prescription was filled on the date after
the prescription was received by the pharmacy and taken until the last day supplied. We assumed
that extended-release naltrexone was active for 28 days from the date of injection.
Because the MarketScan data do not differentiate between patients who were receiving
naltrexone for OUD as opposed to AUD, we further stratified between patients with existing AUD
diagnoses at the time of OUD pharmacologic treatment initiation or during the 6 months preceding
treatment initiation, and those without recent AUD diagnoses. AUD diagnoses were identified by
insurance claims using ICD-9 and ICD-10 codes during any inpatient or outpatient encounter.
For the purposes of sample description, we also obtained data on time-invariant variables, such
as age, sex, and insurance status, which were compared among the subsamples with and without
recent AUD claims. Because the case-control design allows for individuals to serve as their own
control, we did not adjust for these time-invariant variables in our models. However, we included
time-varying covariates corresponding to prescriptions for medications commonly found in alcohol
and drug poisonings23; these included muscle relaxants, antispasmodics, opioids (not buprenorphine
or methadone), antidepressants, mood stabilizers, antipsychotics, nonsteroidal anti-inflammatory
drugs, and benzodiazepines (eTable 1 in the Supplement). The logic for including these was 2-fold.
First, any interaction between these medications and OUD medications may be associated with the
point estimates for the OUD medications. Second, use of these medications may serve as proxy
variables for comorbidities that can be measured with greater frequency than diagnoses.

Statistical Analysis
We calculated descriptive statistics for the primary analytical sample using χ2 and Kruskal-Wallis
tests, which were stratified by recent AUD claims. For our primary analysis, we used a case-control
approach described by Allison et al24 that includes all observed days limited to 365 days before and
after the index alcohol-related acute event already described. Thus, case days included the index
event and any subsequent event, whereas control days included all other days within the observation
window. An overview of repeated-event, case-control design is illustrated in the eFigure in the
Supplement. Models to estimate the odds ratio (OR) describing the association between events and
OUD medication exposure days were estimated using conditional logistic regression, with each
person serving as the stratification (conditioning) variable. Medication days were coded as 1, and
nonmedication days were coded as 0 (reference group). This approach is analogous to a stratified
Cox-regression with recurrent events.24 As a recurrent-event approach, our analysis allowed for
incorporation of time (days since index event) as a covariate, mitigating secular confounding that is
often a concern with single-event, case-control studies.24-26 We controlled for secular time trends
using restricted cubic splines.27 Unadjusted models included only OUD medications, whereas
adjusted models controlled for exposure medications commonly associated with alcohol
poisonings.23 All P values were derived from 2-sided tests, with significance reached at P < .05.
Statistical analysis was performed using SAS statistical software version 9.4 (SAS Institute) from June
26 through September 28, 2020.
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Results
Sample and Treatment Characteristics
The final study sample contained 13 335 unique patients with OUD (mean [SD] age, 33.1 [13.1] years;
5884 female participants [44.1%]; mean observation time, 627.6 days; 8 424 214 person-days of
observation time) who received OUD medications and had at least 1 alcohol-related acute event.
Table 1 summarizes descriptive statistics at the individual participant level, with stratification by the
presence of recent AUD claims. In total, 19.6% of the sample (2615 individuals) had claims for more
than 1 event. Of all participants, 6299 (47.2%) received buprenorphine in the year before and after
the index event; in comparison, 667 (5.0%) received methadone, 1096 (8.2%) received extendedrelease naltrexone, and 3236 (24.3%) received oral naltrexone. Although all participants had
received OUD medication during insurance enrollment, 2037 (15.3%) did not receive OUD
medication during the 1 year before and after index event that constituted our study’s
observation window.
A total of 55.9% of the sample (7462 participants) had a recent AUD claim before or at start of
OUD treatment, defined by diagnoses within 6 months of the start of treatment. These patients were

Table 1. Treatment Characteristics at the Individual Participant Level During 1 Year Before and After
Index Alcohol-Related Acute Eventa
Participants, No. (%)
Total
(N = 13 335)

OUD with recent
AUD claims
(n = 7462)

OUD without
recent AUD claims
(n = 5873)

P value

Buprenorphine

6299 (47.2)

3134 (42.0)

3165 (53.9)

<.001

Methadone

667 (5.0)

298 (4.0)

369 (6.3)

<.001

Naltrexone extended release

1096 (8.2)

737 (9.9)

359 (6.1)

<.001

Naltrexone oral

3236 (24.3)

2399 (32.2)

837 (14.3)

<.001

None

2037 (15.3)

894 (12.0)

1143 (19.5)

<.001

Characteristic
OUD medication use during 1 y before and 1 y
after index alcohol-related acute event

Use of medications commonly found in
association with alcohol poisonings during
1 y before and 1 y after index alcohol-related
acute event
Muscle relaxant

4579 (34.3)

2462 (33.0)

2117 (36.1)

<.001

Antispasmodic

1667 (12.5)

912 (12.2)

755 (12.9)

.27

Opioid (not or buprenorphine or
methadone)

8543 (64.1)

4812 (64.5)

3731 (63.5)

.25

Antidepressant

10533 (79.0)

6159 (82.5)

4374 (74.5)

<.001

Mood stabilizer

5891 (44.2)

3790 (50.8)

2101 (35.8)

<.001

Antipsychotic

5938 (44.5)

3521 (47.2)

2417 (41.2)

<.001

Nonsteroidal anti-inflammatory drug

6312 (47.3)

3583 (48.0)

2729 (46.5)

.08

Benzodiazepine

7552 (56.6)

4359 (57.7)

3193 (42.3)

<.001

Male

7451 (55.9)

4235 (56.8)

3216 (54.7)

Female

5884 (44.1)

3227 (43.3)

2657 (45.2)

9276 (69.6)

5322 (71.3)

3954 (67.3)

Sociodemographic characteristics
Sex
.02

Insurance
Private insurance
Medicaid

4059 (30.4)

2140 (28.7)

1919 (32.7)

Year of birth

1977

1975

1979

Age, mean (SD), y

33.1 (13.1)

34.9 (12.9)

30.8 (13.1)

1

10 720 (80.4)

5501 (73.7)

5219 (88.9)

2

1639 (12.3)

1167 (15.6)

472 (8.0)

≥3

976 (7.3)

794 (10.6)

182 (3.1)

Abbreviations: AUD, alcohol use disorder; OUD, opioid
use disorder.
a

<.001

<.001

Alcohol-related acute events, No.

<.001
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less likely to receive agonist therapy than their peers without AUD claims (42.0% [3134 participants]
vs 53.9% [3165 participants] for buprenorphine; 4.0% [298 participants] vs 6.3% [369 participants]
for methadone). Conversely, they were more likely to receive naltrexone (oral naltrexone, 32.2%
[2399 participants] vs 14.3% [837 participants]; extended-release naltrexone, 9.9% [737
participants] vs 6.1% [359 participants]). With regard to sociodemographic characteristics,
individuals with recent AUD claims were slightly older (mean [SD] age, 34.9 [12.9] vs 30.8 [13.1]
years), more likely to be male (4235 [56.8%] vs 3216 [54.7%] men), less likely to be enrolled in
Medicaid (2140 [28.7%] vs 1919 [32.7%] participants), and were more likely to incur multiple alcoholrelated events (1967 [26.2%] vs 654 [11.1%] events) (Table 1). Participants with recent AUD claims
also had more prescriptions for antidepressants (6156 [82.5%] vs 4374 [74.5%] participants), mood
stabilizers (3790 [50.8%] vs 2101 [35.8%] participants), antipsychotics (3521 [47.2%] vs 2417 [41.2%]
participants), and benzodiazepines (4359 [57.7%] vs 3193 [42.2%] participants) than participants
without AUD claims.
Table 2 depicts the rate of alcohol-related events, per 100 days, stratified by OUD medication
exposure and by recent AUD claims. In general, event rates were lower for buprenorphine or
methadone treatment days than for days when patients were treated with either naltrexone
formulation or for nonmedication days. For nontreatment days, 0.22% of days overall (mean, 535.0
days per person), 0.25% of days for those with active AUD claims (mean, 534.6 days per person),
and 0.18% of days among those without active AUD claims (mean, 535.6 days per person) were
marked by alcohol-related acute events. For antagonist medications, 0.29% (mean, 15.7 days per
person) of oral naltrexone treatment days (0.28% [mean, 8.2 days per person] for those with active
AUD claims and 0.29% [mean, 21.5 days per person] for those without active AUD claims) and 0.19%
(mean, 6.4 days per person) of extended-release naltrexone treatment days (0.20% [mean, 7.5 days
per person] for those with AUD claims and 0.18% [mean, 5.1 days per person] for those without AUD
claims) were marked by events. Among agonist medications, 0.11% (mean, 8.4 days per person) of
methadone treatment days (0.11% [mean, 5.8 days per person] of days for those with AUD claims
and 0.12% [mean, 11.7 days per person] of days for those without AUD claims) and 0.15% (mean, 62.7
days per person) of buprenorphine treatment days (0.13% of days [mean, 48.9 days per person] for
those with AUD claims and 0.16% [mean, 80.3 days per person] for those without AUD claims) were
marked by alcohol-related acute events.

Association of OUD Medication With Alcohol-Related Acute Events
Figure 2 shows the adjusted ORs of admissions for alcohol-related acute events associated with days
using OUD medications vs nonmedication days. A full listing of point estimates and 95% CIs is
enumerated in eTable 2 (unadjusted models) and eTable 3 (adjusted models) in the Supplement, with

Table 2. Rate of Alcohol-Related Events Associated With OUD Medications, Stratified by Recent AUD Claimsa
Total (N = 8 424 214 person-days
among 13 335 individuals)

OUD with recent AUD claims
(n = 4 629 076 person-days
among 7462 individuals)

OUD without recent AUD claims
(n = 3 795 138 person-days
among 5873 individuals)

Mean
d/person, No.

Rate of alcohol-related Mean
events/100 d
d/person, No.

Rate of alcohol-related
events/100 d

Mean
d/person, No.

Rate of alcohol-related
events/100 d

Buprenorphine

62.7

0.15

48.9

0.13

80.3

0.16

Methadone

8.4

0.11

5.8

0.11

11.7

0.12

Naltrexone extended-release

6.4

0.19

7.5

0.20

5.1

0.18

Naltrexone oral

15.7

0.29

21.5

0.29

8.2

0.28

Nonmedication

535.0

0.22

534.6

0.25

535.6

0.18

All observation days

627.6

0.21

617.5

0.24

640.4

0.18

Variable
Treatment

Abbreviations: AUD, alcohol use disorder; OUD, opioid use disorder.
a

This table depicts the percentage of insurance coverage days entailing an alcohol-related acute event, which is compared among days when participants were receiving
buprenorphine, methadone, naltrexone (extended release or oral), and nonmedication treatment days. These analyses were further stratified between persons who had recent
AUD claims and those without recent AUD claims.
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the association between OUD medication and alcohol-related acute events unchanged between
unadjusted and adjusted analyses. Covariate adjustment had little impact on the other parameters in
the model. Among agonist medications, buprenorphine was associated with a 43% reduction
(OR, 0.57; 95% CI, 0.52-0.61) and methadone was associated a 66% reduction (OR, 0.34; 95% CI,
0.26-0.45) in adjusted odds of alcohol-related acute events. Among antagonist medication, oral
naltrexone was associated with a 37% reduction (OR, 0.63; 95% CI, 0.52-0.76) and extended-release
naltrexone was associated with a 16% reduction (OR, 0.84; 95% CI, 0.76-0.93) in the adjusted odds
of such events.
In the stratified analysis, buprenorphine’s protective associations against alcohol-related acute
events were more pronounced among patients with OUD with recent AUD claims (OR, 0.41; 95%
CI, 0.36-0.46) than among peers without such claims (OR, 0.74; 95% CI, 0.66-0.83). In comparison,
methadone exhibited similar protective associations in patients with OUD with (OR, 0.30; 95% CI,
0.20-0.45) and without (OR, 0.36; 95% CI, 0.25-0.53) recent AUD claims. The protective
associations of extended-release naltrexone (OR, 0.56; 95% CI, 0.45-0.70) and oral naltrexone (OR,
0.79; 95% CI, 0.70-0.88) were significant only among patients with OUD with AUD, as opposed to
peers without claims; however, differences in adjusted ORs by AUD status were not significant
because of wide 95% CIs among patients with AUD. Across all analyses, the 2 forms of naltrexone did
not significantly differ from one another in their association with alcohol-related acute events.

Discussion
Our study shows that OUD treatment days were associated with reductions in overall odds of
admissions for alcohol-related acute events (ie, falls, injuries, and poisonings). We observed risk
reductions of 43% for buprenorphine and 66% for methadone treatment days. Extended-release
and oral naltrexone treatment days were associated with 37% and 16% reductions, respectively.
Naltrexone use was more prevalent among patients with OUD with existing AUD claims than their
peers without such claims, consistent with naltrexone’s dual FDA indications of naltrexone for both
AUD and OUD treatment. However, naltrexone and buprenorphine showed similar overall protective
outcomes against alcohol-related acute events.
Interestingly, our findings illustrate that the greatest overall reduction in alcohol-related acute
events were observed with methadone. Time-varying confounding cannot be ruled out because

Figure 2. Adjusted Odds of Alcohol-Related Acute Events Associated With Opioid Use Disorder (OUD)
Treatment Days Compared With Nontreatment Days

Group

Favors no
alcohol-related
event

Odds ratio
(95% CI)

Favors
alcohol-related
event

All participants
Buprenorphine

0.57 (0.52-0.61)

Methadone

0.34 (0.26-0.45)

Naltrexone extended release

0.63 (0.52-0.76)

Naltrexone oral

0.84 (0.76-0.93)

Participants with recent AUD claim
Buprenorphine

0.41 (0.36-0.46)

Methadone

0.30 (0.20-0.45)

Naltrexone extended release

0.56 (0.45-0.70)

Naltrexone oral

0.79 (0.70-0.88)

Participants without recent AUD claim
Buprenorphine

0.74 (0.66-0.83)

Methadone

0.36 (0.25-0.53)

Naltrexone extended release

0.77 (0.54-1.10)

Naltrexone oral

0.92 (0.74-1.14)
0.1

0.2

0.4

0.8

1.16

Odds ratio (95% CI)
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these results can be partly explained by the structure of opioid treatment programs (ie, methadone
clinics), which frequently monitor alcohol and illicit drug use with urine drug screens. The
effectiveness of OUD medications in AUD may be more limited when it is not accompanied by
psychosocial interventions, such as relapse-prevention therapy or counseling focused on medication
adherence,28 which are seen in opioid treatment programs that dispense methadone. The
association between methadone treatment days and alcohol-related events warrants further
investigation.
Of note, our results should be interpreted in conjunction with known differences in medication
adherence. The true practical effectiveness of antagonist therapies may be hindered by lower
medication adherence associated with naltrexone compared with agonist treatments in the OUD
population. For instance, substantially greater medication adherence has been observed for
buprenorphine treatment (median filled prescriptions of 19 months) compared with both extendedrelease (9 months) and oral (5 months) naltrexone,29 with patients with OUD found to show similar
adherence to methadone and buprenorphine.30 As our study evaluates ORs that describe protective
outcomes associated with medication at a given point in time, the protective outcomes observed in
association with buprenorphine and methadone treatment days are likely to be amplified by their
higher adherence rates compared with naltrexone. However, our analyses rely on the implicit
assumption that risks associated with medication or lack of medication are constant over time. More
investigation is needed to evaluate how these risks might vary before, during, and after OUD
treatment, in addition to investigating the comparative effectiveness of buprenorphine, methadone,
and naltrexone in suppressing alcohol use in patients with OUD.

Limitations and Strengths
There are several limitations to note. First, although the MarketScan data benefit from a large,
national sample with ample longitudinal follow-up, measurement error cannot be ruled out, such that
medication coverage does not always reflect actual consumption. Furthermore, patients with OUD
without observed AUD claims may have a history of treated or untreated AUD not reflected in recent
insurance claims. However, we observed a higher prevalence of naltrexone use in patients with AUD
claims, and we also observed significant differences in OUD medication treatment outcomes
between patients with OUD with recent AUD claims and peers without such claims, suggesting that
the distinction between these 2 groups may be clinically meaningful and thus warrants more
research. Second, unmeasured time-varying factors associated with alcohol-related admissions and
OUD medication exposure can introduce confounding in case-control designs. We mitigated this,
however, by including calendar time and time from event as covariates and restricting participants to
2-year observation periods surrounding the index event in order to reduce heterogeneity in
observation time. We also used bidirectional sampling in order to reduce overlap bias resulting from
control period selection as a function of event time.25 Third, even though self-matching is used by
the case-control design, residual confounding by unmeasured time-invariant variables cannot be
ruled out. Fourth, the MarketScan data only encompass insured patients with observed alcoholrelated acute events, which limits our study’s generalizability.
Despite these limitations, our study was strengthened by its repeated-event, case-control
design, allowing for reduction of selection and sampling bias stemming from conventional
observational study recruitment. In addition, we controlled for conditions leading to alcohol-related
events via adjustment for medications commonly found in association with such events. The
protective associations of buprenorphine, methadone, and naltrexone were not significantly
changed in the adjusted analyses, providing evidence of robustness to measured confounders.

Conclusions
The findings of this study suggest that OUD medications are associated with decreased hospital
admissions for alcohol-related acute events among persons with OUD. Although naltrexone use was
JAMA Network Open. 2021;4(2):e210061. doi:10.1001/jamanetworkopen.2021.0061 (Reprinted)
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more prevalent among patients with OUD with recent AUD claims, agonist treatments
(buprenorphine and methadone) also were associated with fewer alcohol-related events. The
present study raises key questions about the potential of OUD medications for reducing alcoholrelated events and highlights the need for additional research in this area.
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